News
03-06-2010, 02:41 AM
Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.
More... (http://www.news-medical.net/news/20100306/Presentation-of-results-from-open-label-extension-study-of-Xenazine-announced.aspx)
More... (http://www.news-medical.net/news/20100306/Presentation-of-results-from-open-label-extension-study-of-Xenazine-announced.aspx)